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Summary
Background Hydroxychloroquine, a drug commonly used in the treatment of rheumatoid arthritis, has received much 
negative publicity for adverse events associated with its authorisation for emergency use to treat patients with 
COVID-19 pneumonia. We studied the safety of hydroxychloroquine, alone and in combination with azithromycin, to 
determine the risk associated with its use in routine care in patients with rheumatoid arthritis.
Methods In this multinational, retrospective study, new user cohort studies in patients with rheumatoid arthritis aged 
18 years or older and initiating hydroxychloroquine were compared with those initiating sulfasalazine and followed up 
over 30 days, with 16 severe adverse events studied. Self-controlled case series were done to further establish safety in 
wider populations, and included all users of hydroxychloroquine regardless of rheumatoid arthritis status or indication. 
Separately, severe adverse events associated with hydroxychloroquine plus azithromycin (compared with hydroxy-
chloroquine plus amoxicillin) were studied. Data comprised 14 sources of claims data or electronic medical records 
from Germany, Japan, the Netherlands, Spain, the UK, and the USA. Propensity score stratification and calibration 
using negative control outcomes were used to address confounding. Cox models were fitted to estimate calibrated 
hazard ratios (HRs) according to drug use. Estimates were pooled where the I² value was less than 0·4.
Findings The study included 956 374 users of hydroxychloroquine, 310 350 users of sulfasalazine, 323 122 users of 
hydroxychloroquine plus azithromycin, and 351 956 users of hydroxychloroquine plus amoxicillin. No excess risk 
of severe adverse events was identified when 30-day hydroxychloroquine and sulfasalazine use were compared. Self-
controlled case series confirmed these findings. However, long-term use of hydroxychloroquine appeared to be 
associated with increased cardiovascular mortality (calibrated HR 1·65 [95% CI 1·12–2·44]). Addition of azithromycin 
appeared to be associated with an increased risk of 30-day cardiovascular mortality (calibrated HR 2·19 [95% CI 
1·22–3·95]), chest pain or angina (1·15 [1·05–1·26]), and heart failure (1·22 [1·02–1·45]).
Interpretation Hydroxychloroquine treatment appears to have no increased risk in the short term among patients 
with rheumatoid arthritis, but in the long term it appears to be associated with excess cardiovascular mortality. 
The addition of azithromycin increases the risk of heart failure and cardiovascular mortality even in the short term. 
We call for careful consideration of the benefit–risk trade-off when counselling those on hydroxychloroquine 
treatment.
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Martin Escudero, Innovation Fund Denmark, Novo Nordisk Foundation, Singapore Ministry of Health’s National 
Medical Research Council Open Fund Large Collaborative Grant, VINCI, Innovative Medicines Initiative 2 Joint 
Undertaking, EU’s Horizon 2020 research and innovation programme, and European Federation of Pharmaceutical 
Industries and Associations.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
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Introduction
Hydroxychloroquine, which is most commonly used as 
the first-line treatment in patients with autoimmune 
diseases such as rheumatoid arthritis and systemic lupus 
erythematosus (SLE), has gained extensive media coverage 
as a potential antiviral agent for use against severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2), which 
causes COVID-19.1–5 Unfortunately, the exponential gen-
era tion of research into hydroxychloroquine has led to 
confusion in the rheumatological community regarding 
the safety implications of hydroxychloroquine within its 
traditional uses.
Early in the COVID-19 pandemic, publicity focused 
on a study from France6 showing faster recovery and 
reduction in viral load in patients treated with high-
dose hydroxychloroquine plus azithromycin, a macrolide 
anti biotic, compared with patients receiving standard 
treat ment available at the time. This report led to 
widespread use of high-dose hydroxychloro quine either 
alone or with azithromycin. Subsequently, serious cardiac 
adverse events associated with QT segment prolonga tion 
that could lead to potentially lethal arrhythmia and 
cardiovascular-related death were identified in patients 
taking hydroxychloroquine in several health-care centres 
in the USA and Brazil.7–10 Because of these reports of 
increased risk, emergency authorisation of hydroxychloro-
quine by medicines regulators was retracted, statements 
cautioning against hydroxychloroquine use were released, 
and randomised trials were stopped.10–15
European guidelines for the treatment of patients 
with rheumatoid arthritis contain little high-level evidence 
for the safety of hydroxychloroquine, and most syste-
matic reviews of rheumatoid arthritis treatments have 
focused on biological therapies.16,17 Before the COVID-19 
pandemic, evidence for hydroxychloroquine safety was 
largely found in retrospective case series and case reports, 
or within pharmaceutical adverse events registers.18–20 
Azithromycin and macrolides in general are also known 
to induce cardiotoxicity and to interact with other drugs 
that prolong QTc.21–23
The combination of minimal large-scale hydroxy-
chloroquine safety studies before this pandemic, and 
the extensive research suggesting risks associated with 
hydroxy chloroquine use that has been produced dur ing 
2020 is of great concern to both patients and clini-
cians. We there fore aimed to assess the safety of 
hydroxychloroquine alone compared with sulfasalazine 
and of hydroxychloroquine in combination with azithro-
mycin (compared with hydroxychloroquine in com-
bination with amoxicillin), in part to provide clarity for 
patients taking hydroxychloroquine for rheumatoid 
arthritis.
Methods
Study design and participants
In this multinational, retrospective study, new user cohort 
studies were used as recommended by methodological 
guidelines24 for observational drug safety research to 
estim ate the safety of hydroxychloroquine alone or in 
combina tion with macrolide antibiotics in patients with 
rheuma toid arthritis. Sulfasalazine and amoxicillin were 
chosen as active comparators because they have simi-
lar indica tions as the target treatments (hydroxychloro -
quine and azithromycin, respectively). Participants were 
included if they had a history of rheumatoid arth-
ritis (a con di tion occurrence or observation indicating 
Research in context
Evidence before this study
We systematically searched PubMed, Embase, clinical trial 
registries (ClinicalTrials.gov, the International Clinical Trials 
Registry Platform Search Portal, and the Chinese Clinical Trial 
Registry), and preprint servers (bioRxiv and medRxiv) from 
inception until March 27, 2020 (appendix pp 126–30) for 
research articles in English, Chinese, Spanish, and Italian (see 
appendix p 126 for search terms). No contemporary large-scale 
evidence was found that investigated the real-world safety of 
hydroxychloroquine compared with other first-line disease-
modifying antirheumatic drugs, especially in combination with 
macrolide antibiotics such as azithromycin, which have been 
proposed for use as a treatment for COVID-19. Systematic 
reviews that have informed European guidelines focused on 
severe adverse events associated with biological therapies with 
little high-level evidence focused on hydroxychloroquine. 
Severe cardiovascular adverse events, mostly lethal arrhythmias 
and heart failure, have been described in independent 
retrospective case series and case reports, and reported within 
the US Food and Drug Administration adverse events database.
Added value of this study
This study uses state-of-the-art methods to control for residual 
confounding and bias and shows comparable results across 
14 international health databases. Hydroxychloroquine does 
not seem to confer increased risk when used in patients with 
rheumatoid arthritis without contraindications in the short 
term (up to 30 days) compared with sulfasalazine, but confers 
an increased risk of cardiovascular mortality when used long 
term. Short-term treatment with hydroxychloroquine plus 
azithromycin appears to be associated with elevated risk of 
cardiovascular mortality, angina, and heart failure compared 
with hydroxychloroquine plus amoxicillin.
Implications of all the available evidence
Short-term use of hydroxychloroquine appears to confer no 
increased risk in patients with rheumatoid arthritis without 
contraindications, but hydroxychloroquine in combination with 
azithromycin appears to be associated with serious 
cardiovascular adverse events and should therefore be used 
with caution.
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rheumatoid arthritis any time before or on the same day 
as therapy initiation), were aged 18 years or older at the 
index event, and had at least 365 days of continuous 
observation time before the index event.
As a secondary analysis, a self-controlled case series 
was used to estimate the safety of hydroxychloroquine 
in the wider population, including patients without 
rheuma toid arthritis. For this analysis, all prevalent users 
of hydroxychloroquine were included, regardless of 
rheumatoid arthritis status or indication.
All data partners received approval or waiver from 
their institutional review boards in accordance with their 
institutional governance guidelines. The full study protocol 
is available online.
Data sources
Electronic health records (EHRs) and administrative 
claims data were mapped to the Observational Medical 
Outcomes Partnership common data model (version 5.0 
or higher) and analysed in a distributed network as part of 
an international effort with the Observational Health Data 
Science and Informatics community, including 14 
databases: IQVIA (Durham, NC, USA) Disease Analyzer 
Germany (ambulatory electronic medical record [EMR] 
from Germany); Japanese Medical Data Center Claims 
Database (Tokyo, Japan); Integrated Primary Care 
Information (IPCI; Rotterdam, Netherlands; primary care 
EMR); Information System for the Development of 
Research in Primary Care (SIDIAP; Barcelona, Spain; 
primary care EMR); Clinical Practice Research Datalink 
(CPRD; London, UK) and IQVIA UK (London, UK) 
Integrated Medical Record Data (IMRD; primary care 
EMRs); and IBM MarketScan (Somers, NY, USA) 
Commercial Claims and Encounters (CCAE), Optum 
(Eden Prairie, MN, USA) de-identified Clinformatics Data 
Mart Database (Clinformatics), Optum EHR (Optum 
de-identified Electronic Health Record dataset), IBM 
MarketScan Medicare Supplemental Database (MDCR), 
IBM MarketScan Multi-State Medicaid Database (MDCD), 
IQVIA Open Claims, US Department of Veterans Affairs 
(VA; Salt Lake City, UT, USA), and IQVIA US Ambulatory 
EMR (USA).
Self-controlled case series were done on a subset of 
these databases as a secondary analysis: CCAE, CPRD, 
Clinformatics, MDCD, MDCR, and VA. A description of 
these data sources is available in the appendix (pp 3–4).
Study period and outcomes
The study period started from Sept 1, 2000, and ended at 
the latest available date for all data sources in 2020. Follow-
up for each of the cohorts started at an index date defined 
by the first dispensing or prescription of the target or 
comparator drug as described in the cohort definitions 
(appendix pp 5–8). Two periods were considered to define 
time at risk. For a short-term, intention-to-treat analysis, 
follow-up started 1 day after the index date and continued 
until the first of: outcome of interest, loss to follow-up, or 
30 days after the index date to resemble the duration of 
COVID-19 treatment regimens.6 For a longer-term, on-
treatment analysis, follow-up started 1 day after the index 
date and continued until the earliest of: outcome of 
interest, loss to follow-up, or discontinuation, with an 
added washout time of 14 days. Continued use of the same 
treatment was inferred by allowing up to 90-day gaps 
between dispensing or prescription records. Addi tional 
detail on the exposure cohorts is available in the 
appendix (pp 5–8).
For self-controlled case series, periods of persistent 
exposure to hydroxychloroquine were generated allowing 
up to 90-day gaps between dispensing or prescription 
records. Patients were followed up for their entire observa-
tion time (eg, from enrolment to disenrolment in each 
data base), and rates of each of the outcomes calculated in 
periods of exposure and non-exposure time.
The proposed code lists for the identification of the study 
population and for the study exposures were created by 
clinicians with experience in the management of rheuma-
toid arthritis using ATLAS, and reviewed by four clinicians 
and one epidemiologist.25
16 severe adverse events were analysed. Hospital-based 
events, which are not available in primary care records 
(CPRD, IMRD, and SIDIAP), included gastrointestinal 
bleeding, acute renal failure, acute pancreatitis, myocardial 
infarction, stroke, transient ischaemic attack, and cardio-
vascular events (composite). Additionally, angina or chest 
pain, heart failure, cardiac arrhythmia, brady cardia, venous 
thromboembolism, end-stage renal disease, and hepatic 
failure were analysed from both primary and secondary 
care data. All-cause mortality outcomes were obtained only 
from data sources with reliable informa tion on death date 
(CPRD, IMRD, IPCI, Clinformatics, SIDIAP, and VA) and 
cardiovascular mortality outcomes from sources with 
information on cardiovascular events preceding death 
(CPRD, IMRD, Clinformatics, and VA). All codes for the 
identification of the 16 proposed study outcomes were 
based on a previously published paper26 and are detailed in 
the appendix (pp 8–9). Face validity for each of the outcome 
cohorts was further reviewed and compared with previous 
clinical knowledge and existing literature.
A list of negative control outcomes was also assessed for 
which there is no known causal relationship with any of 
the drugs of interest. These outcomes were identified 
using a semi-automatic process based on data extracted 
from the literature, product labels, and spontaneous 
reports, and confirmed by manual review by three clini-
cians (JCEL, AP-U, and DP-A).27 A full list of the codes 
that were used to identify negative control outcomes and 
details on covari ate and confounder identification are 
provided in the appendix (pp 10–11).
Statistical analysis
We used propensity score stratification (into quintiles) to 
adjust for observed confounders, using a large-scale 
regular ised logistic regression fitted with a LASSO 
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For the protocol see https://
github.com/ohdsi-studies/
Covid19EstimationHydroxychloro 
quine/tree/master/documents
See Online for appendix
penalty and with the optimal hyperparameter deter-
mined through ten-fold cross-validation.28 Baseline 
patient character istics were constructed for inclusion as 
potentially con found ing covariates.29 Predictor variables 
included were based on all observed patient characteristics 
as available in each data source, including conditions, 
procedures, visits, observations, and measurements. We 
plotted the propensity score distribution and assessed 
covariate balance expressed as the standardised difference 
of the mean for every covariate before and after propensity 
score stratification. A standardised difference of more 
than 0·1 indicated a non-negligible imbalance between 
exposure cohorts.30 Cox proportional hazards models 
conditioned on the propensity score strata were fitted to 
esti mate hazard ratios (HRs) according to treat ment 
status. Negative control outcomes analyses and empir i cal 
calibration were used to minimise potential unresolved 
confounding, with calibra ted HRs and 95% CIs 
estimated.31,32
For self-controlled case series, safety of hydroxychloro-
quine therapy was assessed separately as a secondary 
analysis, regardless of indication, comparing exposed 
and unexposed time periods within the same individuals. 
The method is self-controlled in that it makes within-
person comparisons of event rates during periods of 
hypothesised increased risk with other periods of base-
line risk, which eliminates all time-invariant confound-
ing. Because we do not compare between individuals, the 
self-controlled case series is robust to between-person 
differences, even including unmeasured differences 
(such as genetics). However, the method is vulnerable to 
time-varying confounders. To adjust for this confounding, 
we included many time-varying covariates in the models, 
including age, season, and other drug exposures. A 
conditional Poisson regression was used to fit the out-
come model using the Cyclops package (version 2.0), 
with a hyper para meter selected through ten-fold cross-
validation.33
Study diagnostics (power, propensity score distribution, 
covariate balance, and empirical null distribu tion) were 
evaluated by clinicians and epidemiologists to deter-
mine which database target comparator outcome analysis 
variants could produce unbiased estimates (appendix 
pp 104–18). Analyses with zero event outcomes or with 
confounder imbalances with standardised mean differ-
ence of more than 0·1 after stratification were excluded 
from analysis. All analyses were conducted for each 
database separately, with estimates combined in random-
effects meta-analysis methods where the I² value was less 
than 0·4.34 The standard errors of the database-specific 
estimates were adjusted to incor porate estimate variation 
across databases, where the across-database variance was 
estimated by comparing each database-specific result 
to that of an inverse-variance, fixed-effects meta-analysis. 
No meta-analysis was done where I² for a given drug–
outcome pair was 0·4 or more. Of note, when running 
analysis in a distributed network, it was not possible to 
link across datasets, and to know the extent of overlap 
between data.
Small cell counts (n) of less than five (and resulting 
estimates) are reported as <n to minimise risk of re-
identification. For the cohort analysis, the CohortMethod 
package (version 3.1.0) was used as well as the Cyclops 
HCQ vs SSZ HCQ plus AZM vs HCQ plus AMX
HCQ 
(n=66 604)
SSZ 
(n=22 370)
Standardised 
mean 
difference
HCQ plus 
AZM 
(n=32 586)
HCQ plus 
AMX 
(n=32 496)
Standard 
mean 
difference
Age, years
15–19 0·6% 0·6% 0·00 0·5% 0·5% <0·00
20–24 1·8% 2·0% –0·01 1·4% 1·4% <0·00
25–29 2·5% 2·7% –0·01 2·2% 2·2% <0·00
30–34 4·5% 4·4% <0·00 4·0% 3·9% 0·01
35–39 7·1% 7·1% 0·00 6·8% 6·7% <0·00
40–44 9·7% 9·5% 0·01 9·3% 9·3% <0·00
45–49 13·6% 13·4% <0·00 13·2% 13·3% <0·00
50–54 18·2% 18·1% 0·01 18·1% 18·0% <0·00
55–59 20·8% 20·8% <0·00 21·5% 21·8% –0·01
60–64 19·4% 19·8% –0·01 21·1% 21·1% <0·00
65–69 1·8% 1·6% 0·01 2·0% 2·0% <0·00
Sex
Female 80·1% 79·7% 0·01 86·3% 86·2% 0·00
Male 19·9% 20·3% 0·01 13·7% 13·8% 0·00
Medical history: general
Chronic obstructive lung 
disease
4·3% 4·5% –0·01 5·0% 5·2% –0·01
Depressive disorder 13·3% 13·5% <0·00 14·7% 14·8% <0·00
Diabetes 13·6% 13·8% –0·01 13·2% 13·1% <0·00
Hyperlipidaemia 31·2% 31·4% <0·00 30·4% 30·3% <0·00
Pneumonia 4·0% 4·0% <0·00 5·7% 5·5% 0·01
Renal impairment 3·0% 2·8% 0·01 4·2% 4·1% <0·00
Urinary tract infections 11·6% 11·5% <0·00 14·0% 13·9% <0·00
Medical history: cardiovascular disease
Atrial fibrillation 1·4% 1·3% 0·01 1·7% 1·8% <0·00
Cerebrovascular disease 2·8% 2·9% –0·01 3·1% 3·2% –0·01
Coronary arteriosclerosis 4·4% 4·6% –0·01 5·0% 4·9% <0·00
Heart disease 15·5% 15·4% <0·00 17·8% 17·9% <0·00
Heart failure 1·9% 2·0% <0·00 2·5% 2·4% 0·01
Ischaemic heart disease 3·0% 3·1% –0·01 3·3% 3·1% 0·01
Medication use
Agents acting on the 
renin–angiotensin system
24·5% 24·6% <0·00 27·1% 26·9% <0·00
Antidepressants 36·3% 36·5% <0·00 43·0% 42·8% <0·00
Drugs for obstructive 
airway diseases
29·5% 29·5% <0·00 41·1% 40·7% 0·01
Immunosuppressants 43·4% 43·6% <0·00 51·1% 51·2% <0·00
Opioids 39·0% 39·3% –0·01 41·4% 41·2% <0·00
Psycholeptics 33·4% 33·3% <0·00 38·2% 38·1% <0·00
Percentages might not sum to 100% because of rounding. An example of one dataset is included. AMX=amoxicillin. 
AZM=azithromycin. CCAE=IBM Commercial Claims and Encounters. HCQ=hydroxychloroquine. SSZ=sulfasalazine.
Table 1: Baseline characteristics of users of HCQ versus SSZ, and HCQ plus AZM versus HCQ plus AMX after 
propensity score stratification in the CCAE database
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package (version 2.0) for propensity score estimation.33 
All self-controlled case series were run using the self-
controlled case series package.35 The full source code for 
analyses is available online.
This study is registered with the EU Post-Authorisation 
Studies Register, EUPAS34497.36
Role of the funding source
The funders of the study had no role in study design, data 
collection, data analysis, data interpretation, writing of 
the manuscript, or the decision to submit for publication. 
All authors had full access to aggregated data in the study, 
and the lead and senior authors (JCEL, JW, PRy, and 
30-day follow-up On-treatment follow-up
HCQ  
users
SSZ users HCQ 
events
SSZ 
events
HCQ 
incidence 
rate (per 
1000 
person-
years)
SSZ 
incidence 
rate (per 
1000 
person-
years)
HCQ 
users
SSZ users HCQ 
events
SSZ 
events
HCQ 
incidence 
rate (per 
1000 
person-
years)
SSZ 
incidence 
rate (per 
1000 
person-
years)
Cardiovascular-related mortality
Clinformatics 51 280 17 389 16 <5 3·85 <3·54 51 280 17 389 234 25 4·39 2·00
CPRD NA NA NA NA NA NA 9127 11 398 7 25 0·39 0·94
VA 32 028 14 349 9 <5 3·43 <4·25 32 028 14 349 315 65 5·69 3·71
Meta-analysis 83 308 31 738 25 <10 3·68 <3·86 92 435 43 136 556 115 4·39 2·03
All-cause mortality
Clinformatics 51 280 17 389 20 10 4·81 7·09 51 280 17 389 527 66 9·88 5·29
CPRD 9127 11 398 6 5 8·03 5·35 9127 11 398 253 386 14·02 14·56
IMRD 8851 8460 <5 6 <6·91 8·66 8851 8460 214 241 12·32 12·72
VA 32 028 14 349 45 17 17·13 14·45 32 028 14 349 1356 327 24·51 18·65
Meta-analysis 101 286 51 596 <76 38 <9·20 9·02 NA NA NA NA NA NA
Chest pain or angina
AmbEMR 57 140 15 268 122 31 26·04 24·76 57 140 15 268 451 112 24·44 19·89
CCAE 65 935 22 173 440 143 82·41 79·62 65 935 22 173 3354 810 55·00 58·80
Clinformatics 50 698 17 221 396 166 96·62 119·34 50 698 17 221 3185 829 66·13 72·48
CPRD 9114 11 388 10 17 13·40 18·22 9114 11 388 260 422 14·99 16·78
DAGermany 3884 5045 <5 5 <15·69 12·07 3884 5045 31 36 12·36 10·26
IMRD 8843 8452 9 10 12·45 14·46 8843 8452 235 293 14·00 16·25
MDCD 7982 2177 80 23 123·50 130·43 7982 2177 467 100 87·34 85·81
MDCR 15 690 5150 129 49 101·25 117·43 15 690 5150 1178 279 71·38 75·12
OpenClaims 617 628 182 776 2674 804 52·83 53·68 617 628 182 776 31 161 6198 38·59 38·11
OptumEHR 76 844 21 549 629 143 101·46 82·23 NA NA NA NA NA NA
VA 31 824 14 276 130 54 49·89 46·20 31 824 14 276 1822 611 35·88 37·31
Meta-analysis 945 582 305 475 <4624 1445 <59·86 57·90 868 738 283 926 42 144 9690 40·36 37·07
Heart failure
AmbEMR 57 383 15 305 42 10 8·92 7·96 57 383 15 305 182 53 9·76 9·37
CCAE 66 604 22 370 30 5 5·55 2·75 66 604 22 370 305 74 4·64 5·07
Clinformatics 51 204 17 356 84 25 20·23 17·76 51 204 17 356 915 207 17·55 16·90
CPRD 9126 11 397 <5 <5 <6·69 <5·35 9126 11 397 16 36 0·89 1·36
DAGermany 3885 5042 <5 <5 <15·68 <12·08 3885 5042 11 22 4·29 6·22
IMRD 8852 8460 <5 <5 <6·91 <7·22 8852 8460 15 21 0·86 1·11
MDCD 8072 2195 15 <5 22·81 <27·99 8072 2195 118 28 20·55 23·02
MDCR 15 808 5171 39 19 30·30 45·22 15 808 5171 586 141 33·13 36·29
OpenClaims 620 244 183 350 749 214 14·71 14·22 620 244 183 350 12 246 2246 14·36 13·22
OptumEHR 77 813 21 768 237 50 37·64 28·39 NA NA NA NA NA NA
VA 31 895 14 307 56 17 21·42 14·49 31 895 14 307 897 296 16·75 17·42
Meta-analysis 950 886 306 721 <1267 <360 <16·28 <14·34 873 073 284 953 15 291 3124 13·85 11·43
AmbEMR=IQVIA Ambulatory EMR. CCAE=IBM Commercial Claims and Encounters. CPRD=Clinical Practice Research Datalink. DAGermany=IQVIA Disease Analyzer Germany. 
EMR=electronic medical record. HCQ=hydroxychloroquine. IMRD=IQVIA UK Integrated Medical Record Data. MDCD=IBM Multi-state Medicaid. MDCR=IBM Medicare 
Supplemental Database. NA=non-applicable (not reported because of failed diagnostics or on-treatment follow-up unavailable). OptumEHR=Optum de-identified Electronic 
Health Record. SSZ=sulfasalazine. VA=US Department of Veterans Affairs. 
Table 2: Patient counts, event counts, and incidence rates of key outcomes according to HCQ versus SSZ use
For the CohortMethod package 
see https://ohdsi.github.io/
CohortMethod/
For the Cyclops package see 
https://ohdsi.github.io/Cyclops
For the self-controlled case 
series see https://ohdsi.github.
io/SelfControlledCaseSeries/
For the full source code see 
https://github.com/ohdsi-
studies/Covid19Estimation 
Hydroxychloroquine
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DP-A) had final responsibility for the decision to submit 
for publication. 
Results
956 374 hydroxychloroquine and 310 350 sulfasalazine 
users were identified, and 323 122 and 351 956 contributed 
to the analyses of com bination therapy of hydroxychlor-
oquine plus azithromycin compared with hydroxychlor-
oquine plus amoxicillin, respectively. Participant counts 
in each data source are provided in the appendix (pp 13–65). 
Duration of hydroxychloroquine therapy in the long-term 
analysis varied between databases, and ranged from a 
median of 43 days (IQR 43–193) in IQVIA US Ambulatory 
EMR to 338 days (106–1507) in CPRD. Full details can be 
found in the power tab for each database online. 
Compared with sulfasalazine, users of hydroxychloro-
quine were more likely to be female (eg, 82·0% vs 74·3% 
in CCAE) and less likely to have certain comorbidities 
30-day follow-up On-treatment follow-up
HCQ plus 
AZM 
users
HCQ plus 
AMX 
users
HCQ plus 
AZM 
events
HCQ plus 
AMX 
events
HCQ plus AZM 
incidence rate 
(per 1000 
person-years)
HCQ plus AMX 
incidence rate 
(per 1000 
person-years)
HCQ plus 
AZM 
users
HCQ plus 
AMX 
users
HCQ plus 
AZM 
events
HCQ plus 
AMX 
events
HCQ plus AZM 
incidence rate 
(per 1000 
person-years)
HCQ plus AMX 
incidence rate 
(per 1000 
person-years)
Cardiovascular-related mortality
Clinformatics 23 597 24 521 9 6 4·70 3·02 23 597 24 521 96 82 5·56 5·58
VA 6234 8005 46 18 90·60 27·49 6234 8005 157 115 14·60 10·20
Meta-analysis 29 831 32 526 55 24 22·70 9·08 29 831 32 526 253 197 9·03 7·59
All-cause mortality
Clinformatics 23 597 24 521 17 17 8·88 8·55 23 597 24 521 268 276 15·56 18·85
VA 6234 8005 91 52 179·23 79·42 6234 8005 550 518 51·16 45·97
Meta-analysis 29 831 32 526 108 69 44·58 26·12 29 831 32 526 818 794 29·24 30·64
CCAE 32 610 32 507 13 11 4·92 4·17 32 610 32 507 117 94 4·33 4·33
Clinformatics 23 565 24 484 30 29 15·70 14·62 23 565 24 484 179 147 10·60 10·19
MDCD 3803 3808 <5 6 <16·21 19·40 3803 3808 29 27 11·46 13·46
MDCR 8119 9254 16 9 24·33 11·96 8119 9254 166 140 20·41 17·34
Open Claims 216 028 232 938 182 173 10·26 9·05 216 028 232 938 2065 1732 8·11 7·94
OptumEHR 18 477 16 424 26 20 17·35 15·01 NA NA NA NA NA NA
VA 6203 7978 33 19 65·53 29·15 6203 7978 154 127 14·79 11·59
Meta-analysis 308 805 327 393 <305 267 <12·08 9·97 290 328 310 969 2710 2267 8·48 8·24
Chest pain or angina
AmbEMR 13 093 12 028 32 21 29·80 21·29 13 093 12 028 142 119 25·69 25·31
CCAE 32 165 32 229 241 211 92·76 80·98 32 165 32 229 1402 1145 60·46 60·54
Clinformatics 23 206 24 254 244 203 130·28 103·70 23 206 24 254 1019 887 70·33 70·28
MDCD 3712 3764 30 37 99·97 121·56 3712 3764 129 113 60·05 63·39
MDCR 7991 9195 81 85 125·60 114·20 7991 9195 517 498 74·83 71·25
OpenClaims 214 494 231 851 1050 888 59·76 46·74 214 494 231 851 8348 7223 36·24 36·37
OptumEHR 18 039 16 191 218 134 150·01 102·42 NA NA NA NA NA NA
VA 6121 7912 58 50 116·96 77·52 6121 7912 340 371 38·48 39·87
Meta-analysis 318 821 337 424 1954 1629 75·13 59·12 300 782 321 233 11 897 10 356 40·82 40·95
Heart failure
AmbEMR 13 152 12 053 16 16 14·83 16·18 13 152 12 053 61 49 10·44 9·96
CCAE 32 586 32 496 30 23 11·36 8·73 32 586 32 496 177 126 6·58 5·82
Clinformatics 23 541 24 468 65 49 34·08 24·73 23 541 24 468 337 317 20·33 22·63
MDCD 3796 3795 16 9 52·08 29·21 3796 3795 65 48 26·26 24·83
MDCR 8085 9239 45 33 68·88 43·97 8085 9239 322 295 41·61 38·34
OpenClaims 215 732 232 725 472 370 26·68 19·38 215 732 232 725 4352 3714 17·50 17·43
OptumEHR 18 054 16 298 99 60 67·77 45·45 NA NA NA NA NA NA
VA 6164 7959 79 31 158·53 47·73 6164 7959 280 229 28·17 21·64
Meta-analysis 321 110 339 033 822 591 31·32 21·32 303 056 322 735 5594 4778 17·58 17·44
AmbEMR=IQVIA Ambulatory EMR. AMX=amoxicillin. AZM=azithromycin. CCAE=IBM Commercial Claims and Encounters. CPRD=Clinical Practice Research Datalink. DAGermany=IQVIA Disease Analyzer Germany. 
EMR=electronic medical record. HCQ=hydroxychloroquine. IMRD=IQVIA UK Integrated Medical Record Data. MDCD=IBM Multi-state Medicaid. MDCR=IBM Medicare Supplemental Database. NA=non-applicable 
(not reported because of failed diagnostics or on-treatment follow-up unavailable). OptumEHR=Optum de-identified Electronic Health Record. VA=US Department of Veterans Affairs. 
Table 3: Patient counts, event counts, and incidence rates of key outcomes according to HCQ plus AZM versus HCQ plus AMX use
For details see http://evidence.
ohdsi.org:3838/Covid19 
EstimationHydroxychloroquine/
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such as Crohn’s disease (0·6% vs 1·8% in CCAE) or 
psoriasis (3·0% vs 8·9% in CCAE; appendix pp 15–16). In 
CCAE, the mean baseline dose for hydroxychloroquine 
was 420 mg (SD 463), and 2·8% of patients had an 
estimated dose of more than 500 mg. All differences were 
minimised after propensity score strati fication, with all 
reported analyses balanced on all identi fied confounders. 
For example, systemic cortico steroid use or a diagnosis of 
SLE in the year before hydroxychloroquine or sulfasalazine 
use before propen sity score matching was imbalanced 
but was balanced through propensity score stratifica-
tion. Full details of all of the variables used within the 
propensity score are available in the shiny application 
(population characteristics tab, searching for the variable 
within the raw setting). Similarly, users of combina-
tion hydroxychloroquine plus azithromycin differed from 
those of hydroxychloro quine plus amoxicillin, with a 
higher prevalence of acute respiratory disease among 
azithromycin users (eg, 62·5% vs 50·7% in CCAE; 
appendix p 43). Again, propensity score methods miti-
gated these differences, and compar ison groups became 
balanced for all observed confounders after stratification. 
Detailed baseline char ac ter istics for the two pairs of 
treatment groups after propensity score stratification in 
CCAE are detailed in table 1 for illustrative purposes, and 
a complete list of features for each data base compar-
ing before and after propensity score stratification are 
provided in the appendix (pp 13–65). Propensity score 
distribution plots and negative control outcome analyses 
can be found in the appendix (pp 104–118) in addition to 
all elements of the propensity model and Kaplan-Meier 
analyses.
Database-specific and subtotal (meta-analysis) counts 
and rates of key outcomes (cardiovascular mortality, 
Figure 1: Meta-analytic estimates for HCQ versus SSZ and HCQ plus AZM versus HCQ plus AMX new users during 30-day (intention-to-treat) and long-term 
(on-treatment) follow-up
AMX=amoxicillin. AZM=azithromycin. HCQ=hydroxychloroquine. HR=hazard ratio. SSZ=sulfasalazine.
HCQ vs SSZ HCQ plus AZM vs HCQ plus AMX
30-day follow-up
On-treatment follow-up
All-cause mortality
Myocardial infarction
Cardiovascular events
Cardiac arrhythmia
Bradycardia
Transient ischaemic attack
Stroke
Venous thromboembolism
Gastrointestinal bleeding
Acute renal failure
End-stage renal disease
Hepatic failure
Acute pancreatitis
All-cause mortality
Myocardial infarction
Cardiovascular events
Bradycardia
Transient ischaemic attack
Stroke
Venous thromboembolism
Gastrointestinal bleeding
Acute renal failure
End-stage renal disease
Hepatic failure
Acute pancreatitis
Calibrated HR 
(95% CI)
Calibrated HR
(95% CI)
I2
0·76 (0·44−1·32) 0·21
1·15 (0·92−1·43) <0·01
<0·01
<0·01
<0·01
<0·01
<0·01
<0·01
<0·01
<0·01
<0·01
0·11
<0·01
··
··
··
··
··
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<0·01
<0·01
<0·01
<0·01
  0·30
0·29
<0·01
<0·01
I2
<0·01
<0·01
<0·01
0·20
<0·01
0·17
0·03
<0·01
<0·01
<0·01
0·19
<0·01
0·29
<0·01
<0·01
<0·01
<0·01
<0·01
0·28
0·13
0·07
<0·01
1·01 (0·87−1·16)
0·90 (0·78−1·03)
0·88 (0·66−1·16)
1·17 (0·90−1·53)
1·16 (0·93−1·45)
0·96 (0·81−1·13)
1·09 (0·89−1·33)
1·03 (0·88−1·20)
1·07 (0·59−1·93)
0·67 (0·45−1·01)
0·97 (0·72−1·30)
1·11 (0·86−1·44)
1·02 (0·79−1·31)
1·09 (0·84−1·42)
1·04 (0·80−1·35)
1·00 (0·77−1·30)
Not reported
Not reported
Not reported
Not reported
Not reported
Not reported
1·18 (0·91−1·52)
1·23 (0·92−1·63)
1·06 (0·79−1·42)
0·99 (0·76−1·29)
0·25 0·5
Favours HCQ
1 2
Favours SSZ
4 0·25 0·5 1 2 4
1·36 (0·94−1·97)
1·07 (0·88−1·30)
0·93 (0·70−1·25)
1·01 (0·71−1·44)
1·11 (0·91−1·36)
0·99 (0·83−1·18)
1·02 (0·85−1·22)
1·14 (0·76−1·69)
0·88 (0·56−1·39)
0·94 (0·69−1·27)
0·95 (0·83−1·08)
1·02 (0·95−1·09)
1·01 (0·95−1·07)
0·92 (0·84−1·00)
1·02 (0·94−1·11)
0·99 (0·92−1·06)
1·06 (0·97−1·15)
1·01 (0·93−1·10)
0·98 (0·93−1·02)
0·93 (0·82−1·05)
0·93 (0·77−1·12)
1·02 (0·92−1·14)
Favours HCQ
plus AZM
Favours HCQ 
plus AMX
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all-cause mortality, chest pain or angina, and heart failure) 
observed in the prespecified 30-day intention-to-treat 
analysis are shown in tables 2 and 3. Mortality risk was 
assessed only using databases with reliable death capture: 
Clinformatics, CPRD, IMRD, IPCI, SIDIAP, and VA. For 
the analysis of hydroxychloroquine versus sulfasalazine, 
four databases (Clinformatics, CPRD, IMRD, and VA) 
were used to analyse all-cause mortality (no events 
were seen in SIDIAP and IPCI), and three databases 
(Clinformatics, CPRD, and VA) were used to analyse 
cardiov ascular mortality. Two databases were used to 
analyse all-cause mortality and cardiovascular mor tality 
for hydroxychloroquine plus azithromycin versus hydroxy-
chloroquine plus amoxicillin (Clinformatics and VA); no 
events were seen in the other datasets. Mortality rates 
ranged from 4·81 per 1000 person-years in hydroxychloro-
quine users in Clinformatics to 17·13 per 1000 person-years 
among hydroxychloroquine users in VA, with 
cardiovascular-specific mortality ranging from 3·43 per 
1000 person-years in hydroxychloroquine users in VA to 
less than 4·25 per 1000 person-years in sulfasalazine 
users in the same data source. Database-specific counts 
and incidence rates for severe adverse events stratified by 
drug use are detailed in full in the appendix (pp 66–71).
Least common outcomes among hydroxychloroquine 
users included bradycardia (eg, incidence rate 0·92 per 
1000 person-years in CCAE) and end-stage renal disease 
(eg, less than 0·92 per 1000 person-years in CCAE), 
whereas most common outcomes were chest pain or 
angina (eg, 82·41 per 1000 person-years in CCAE; table 2) 
and composite cardiovascular events (eg, 17·96 per 
1000 person-years in CCAE).
Database and outcome-specific HRs (uncalibrated and 
calibrated) are reported in full in the form of forest plots in 
Figure 2: Source-specific and meta-analytic-specific severe adverse event risk estimates for HCQ versus SSZ and HCQ plus AZM versus HCQ plus AMX new users during 30-day (intention-to-
treat) follow-up
AmbEMR=IQVIA Ambulatory EMR. AMX=amoxicillin. AZM=azithromycin. CCAE=IBM Commercial Claims and Encounters. CPRD=Clinical Practice Research Datalink. DAGermany=IQVIA Disease 
Analyzer Germany. EMR=electronic medical record. HCQ=hydroxychloroquine. HR=hazard ratio. IMRD=IQVIA UK Integrated Medical Record Data. MDCD=IBM Multi-state Medicaid. MDCR=IBM 
Medicare Supplemental Database. OptumEHR=Optum de-identified Electronic Health Record. SSZ=sulfasalazine. VA=US Department of Veterans Affairs.
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the appendix (pp 72–103). None of the severe adverse 
events appeared to be consistently increased with the 
short-term use of hydroxychloroquine (vs sulfasalazine) in 
the 30-day intention-to-treat analyses (figure 1), with meta-
analytic calibrated HRs ranging from 0·67 (95% CI 
0·45–1·01) for hepatic failure to 1·17 (0·90–1·53) for tran-
sient ischaemic attack, and 1·36 (0·51–3·63) for cardio-
vascular mortality (figure 2). In our published study 
protocol, we decided a priori that meta-analytic estimates 
would only be reported if the I² value was less than 0·4, 
indicating that there was low heterogeneity between the 
results included, and that it was appropriate for them to be 
pooled to produce this final result.36 For all-cause mortality 
in the on-treatment analysis, the I² value was 0·71, 
indicating substantial heterogeneity between results and 
therefore a summary estimate was not reported. The same 
is true for gastrointestinal bleed ing (I²=0·57) and stroke 
(I²=0·58) in the on-treatment analysis.
Similar findings were seen with the long-term (on-
treatment) use of hydroxychloroquine versus sulfasalazine 
(figure 1; figure 3), with the exception of cardiovas cular 
mortality, which appeared to be inconsistent in the 
available databases but increased overall in the hydroxy-
chloroquine group when meta-analysed (pooled calibrated 
HR 1·65 [95% CI 1·12–2·44]).
Self-controlled case series analyses supported the 
findings of the main analysis, while looking at the effect 
of hydroxychloroquine use (on treatment vs off treatment) 
regardless of indication, and therefore includ ing patients 
without rheumatoid arthritis (table 4; full results are 
given in the appendix pp 119–25).
All of the obtained database-specific and outcome-
specific calibrated HRs for the association between 
short-term (on-treatment) use of hydroxychloroquine plus 
azithromycin versus hydroxychloroquine plus amoxicillin 
are depicted as forest plots in the appendix (pp 72–103). 
Figure 3: Source-specific and meta-analytic specific severe adverse event risk estimates for HCQ versus SSZ and HCQ plus AZM versus HCQ plus AMX new users during long-term 
(on-treatment) follow-up
AmbEMR=IQVIA Ambulatory EMR. AMX=amoxicillin. AZM=azithromycin. CCAE=IBM Commercial Claims and Encounters. CPRD=Clinical Practice Research Datalink. DAGermany=IQVIA Disease 
Analyzer Germany. EMR=electronic medical record. HCQ=hydroxychloroquine. HR=hazard ratio. IMRD=IQVIA UK Integrated Medical Record Data. MDCD=IBM Multi-state Medicaid. MDCR=IBM 
Medicare Supplemental Database. OptumEHR=Optum de-identified Electronic Health Record. SSZ=sulfasalazine. VA=US Department of Veterans Affairs.
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Three severe adverse events appeared to be increased 
with the short-term (30-day intention to treat) use 
of hydroxychloroquine plus azithromycin compared with 
hydroxy chloroquine plus amoxicillin: chest pain or angina 
(meta-analytic calibrated HR 1·15 [95% CI 1·05–1·26]), 
heart failure (1·22 [1·02–1·45]), and cardiovascular mor-
tality (2·19 [1·22–3·95]; figure 2).
Full results from each dataset, including power, attrition, 
and population characteristics are available online. This 
site also contains all of the cohort diagnostic tools that 
were examined before unblinding results and before a 
dataset was included in the meta-analyses. Each dataset 
was examined for the risk of observed confounding (within 
the propensity score model, propensity score distribu-
tion, and covariate balance with identified variables) or 
by unobserved confounding (assessing negative control 
variables within analysis of the risk of systematic error) 
before their inclusion. These diagnostic tools can be 
reviewed for each database for each outcome within the 
shiny application of R (version 3.61) in order to give full 
transparency of analysis.
Discussion
To our knowledge, this study is the largest ever analysis 
of the safety of hydroxychloroquine and hydroxychloro-
quine plus azithro mycin worldwide, examining more 
than 950 000 hydroxy chloroquine and more than 
300 000 hydroxy chloroquine plus azithromycin users, 
respec tively. Short-term (up to 30 days) hydroxychloroquine 
treatment among patients with rheumatoid arthritis 
showed no excess risk of any of the considered severe 
adverse events compared with sulfasalazine. Short-term 
treatment is also proposed for COVID-19 therapy and 
might be informed by the experience of treatment in 
patients with rheuma toid arthritis. By comparison, long-
term hydroxychloro quine therapy appears to be associated 
with a relative risk increase in cardiovascular-related 
mortality compared with a roughly equivalent rheumatoid 
arthritis therapy (sulfasalazine; calibrated HR 1·65 [95% CI 
1·12–2·44]). Perhaps more worryingly, compared with 
hydroxychloroquine plus amoxicillin, significant risks 
were identified for the combination of hydroxychloroquine 
plus azithromycin even in the short term: increased risk 
of angina or chest pain (calibrated HR 1·15 [95% CI 
1·05–1·26]) and heart failure (1·22 [1·02–1·45]), and a 
doubled risk of cardio vascular mortality in the first month 
of treatment (2·19 [1·22–3·94]).
A systematic review of reports on the toxicity of 
hydroxychloroquine has identified cardiac side-effects, 
including conduction disorders, heart failure, and ven-
tric ular hypertrophy resulting in 12·9% irreversible 
damage and 30% mortality.19,20 Furthermore, interrogation 
of the US Food and Drug Administration Adverse Event 
Reporting System database identified 357 adverse events 
reported for chloroquine.18 20% of the events reported 
were cardiac and included arrhythmia, sudden cardiac 
death, or heart failure.
CC
AE
Cl
in
fo
rm
at
ic
s
CP
RD
JM
DC
 C
la
im
s D
at
ab
as
e
M
DC
D
M
DC
R
VA
Ca
lib
ra
te
d 
in
cid
en
ce
 
ra
te
 ra
tio
Ca
lib
ra
te
d 
95
%
 C
I
Ca
lib
ra
te
d 
in
cid
en
ce
 
ra
te
 ra
tio
Ca
lib
ra
te
d 
95
%
 C
I
Ca
lib
ra
te
d 
in
cid
en
ce
 
ra
te
 ra
tio
Ca
lib
ra
te
d 
95
%
 C
I
Ca
lib
ra
te
d 
in
cid
en
ce
 
ra
te
 ra
tio
Ca
lib
ra
te
d 
95
%
 C
I
Ca
lib
ra
te
d 
in
cid
en
ce
 
ra
te
 ra
tio
Ca
lib
ra
te
d 
95
%
 C
I
Ca
lib
ra
te
d 
in
cid
en
ce
 
ra
te
 ra
tio
Ca
lib
ra
te
d 
95
%
 C
I
Ca
lib
ra
te
d 
in
cid
en
ce
 
ra
te
 ra
tio
Ca
lib
ra
te
d 
95
%
 C
I
(C
on
tin
ue
d 
fro
m
 p
re
vi
ou
s p
ag
e)
Ca
rd
io
va
sc
ul
ar
 e
ve
nt
s
Ad
ju
st
ed
 a
na
ly
sis
*
N
A
N
A
0·
90
0·
37
–2
·2
1
N
A
N
A
0·
51
0·
21
–1
·2
5
0·
91
0·
73
–1
·1
5
1·
10
0·
87
–1
·4
0
N
A
N
A
Pr
im
ar
y 
an
al
ys
is
0·
86
0·
66
–1
·1
4
0·
95
0·
69
–1
·3
1
N
A
N
A
0·
50
0·
20
–1
·2
5
0·
86
0·
68
–1
·0
8
1·
02
0·
80
–1
·2
9
1·
08
0·
80
–1
·4
6
Tr
an
si
en
t i
sc
ha
em
ic
 a
tt
ac
k
Ad
ju
st
ed
 a
na
ly
sis
*
0·
91
0·
69
–1
·2
0
0·
94
0·
68
–1
·3
0
N
A
N
A
N
A
N
A
0·
94
0·
72
–1
·2
3
1
0·
79
–1
·2
8
N
A
N
A
Pr
im
ar
y 
an
al
ys
is
0·
92
0·
70
–1
·2
1
0·
93
0·
68
–1
·2
9
N
A
N
A
N
A
N
A
0·
92
0·
71
–1
·2
0
0·
97
0·
76
–1
·2
4
1·
20
0·
88
–1
·6
5
Ve
no
us
 th
ro
m
bo
em
bo
lis
m
Ad
ju
st
ed
 a
na
ly
sis
*
0·
79
0·
54
–1
·1
5
0·
86
0·
62
–1
·1
8
0·
70
0·
45
–1
·0
9
1·
51
0·
62
–3
·6
7
0·
88
0·
71
–1
·1
0
0·
76
0·
60
–0
·9
6
N
A
N
A
Pr
im
ar
y 
an
al
ys
is
0·
81
0·
62
–1
·0
7
0·
84
0·
61
–1
·1
6
0·
69
0·
44
–1
·0
7
1·
51
0·
62
–3
·6
7
0·
87
0·
70
–1
·0
9
0·
71
0·
56
–0
·9
1
0·
86
0·
64
–1
·1
6
CC
AE
=I
BM
 C
om
m
er
cia
l C
la
im
s a
nd
 E
nc
ou
nt
er
s. 
CP
RD
=C
lin
ica
l P
ra
ct
ice
 R
es
ea
rc
h 
Da
ta
lin
k.
 H
CQ
=h
yd
ro
xy
ch
lo
ro
qu
in
e.
 JM
DC
=J
ap
an
es
e 
M
ed
ica
l D
at
a C
en
te
r. 
M
DC
D=
IB
M
 M
ul
ti-
st
at
e 
M
ed
ica
id
. M
DC
R=
IB
M
 M
ed
ica
re
 S
up
pl
em
en
ta
l D
at
ab
as
e.
 
N
A=
no
n-
ap
pl
ica
bl
e 
(n
ot
 re
po
rt
ed
 b
ec
au
se
 o
f f
ai
le
d 
di
ag
no
st
ics
 o
r o
n-
tr
ea
tm
en
t f
ol
lo
w
-u
p 
un
av
ai
la
bl
e)
. V
A=
US
 D
ep
ar
tm
en
t o
f V
et
er
an
s A
ffa
irs
. *
Ad
ju
st
ed
 fo
r e
ve
nt
-d
ep
en
de
nt
 o
bs
er
va
tio
n.
 
Ta
bl
e 4
: S
um
m
ar
y 
of
 se
lf-
co
nt
ro
lle
d 
ca
se
 se
rie
s r
es
ul
ts
 fo
r H
CQ
For full results see 
http://evidence.ohdsi.org/
Covid19Estimation 
Hydroxychloroquine/
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Our results suggest that long-term use of hydroxy-
chloroquine leads to increased cardiovascular mor tality, 
which might relate to cumulative effects of hydroxy-
chloroquine leading to an increased risk of QT lengthening 
and potentially to sudden undetected torsade-de-pointes 
and cardiovascular death. Although long-term treat -
ment with hydroxychloroquine is not expected for the 
management of COVID-19, some research suggests that 
the higher doses prescribed for COVID-19 than for 
rheumatoid arthritis can, even in the short term, lead 
to equivalent side-effects given the long half-life of 
hydroxychloroquine.19
In addition, QT lengthening is a known side-effect of 
all macrolides, including azithromycin, and physi cians 
already use caution when prescribing macrolides con-
currently with other medications that can interact to 
increase the QT interval.22,23 In this study, a relative risk of 
2·19 (95% CI 1·22–3·94) for cardiovascular death was seen 
even with short-term hydroxychloroquine plus azithro-
mycin combination therapy, probably arising through 
their synergistic effects on QT length and subse quent 
induction of lethal arrhythmia. Considering that hydroxy-
chloroquine and azithromycin are both contra indicated 
for use in patients with cardiac arrhythmias, this study 
assumes that clinicians are prescrib ing these medications 
for patients as per existing labelling advice. It is therefore 
concerning that cardio vascular effects were still seen in 
our study popula tions, possibly indicating that the true 
risks of these drugs are understated in the analysis.
It is important to identify potential sources of bias that 
could limit the study. The analyses are predicated on 
observing the presence of exposure, outcomes, and 
covariates in the data, or inferring their absence based on 
an assumption of complete data capture during a defined 
observation period during which a person is not expected 
to be lost to follow-up. In this regard, although there were 
no missing data that required imputation, each binary 
variable is subject to potential misclassification error, and 
the sensitivity and specificity of these variables in each 
database are unknown. Because of the nature of sudden 
cardiac death, capturing the true cause of cardiovascular-
related mortality is difficult. Although we examined 
various aspects of cardiac complications as captured 
by diag nosis codes, the accuracy of evaluations of QT 
prolonga tion, ventricular tachycardia, or other arrhythmias 
would probably be improved with precise electrocardio-
gram measurements. Exposure misclassification can 
occur as a result of non-adherence or non-compliance with 
either treatment and thus could bias the results in either 
direction, and outcome misclassification might exist 
because of incomplete or incorrect recording of severe 
adverse events. Baseline covariates might also be subject to 
measurement error and, although observing balance on all 
baseline characteristics after propensity score adjustment 
provides reassurance that the risk of confounding has 
been reduced, there remains potential for confounding in 
any given source for differential misclassification. The 
consistency of findings across heterogeneous patient 
populations with disparate data capture processes miti-
gates this concern. Within the study design, use of routine 
health-care data in populations across four continents, and 
including all adults with rheumatoid arthritis was used to 
minimise selection bias. The self-controlled case series 
analysis was also added to investigate all users of hydroxy-
chloroquine as an external validation of the hydroxychloro-
quine findings in the rheumatoid arthritis population via 
the new user design. To investigate systematic error, study 
diagnostics were evaluated before unblinding results 
through interrogation of negative controls.
We have taken into consideration that patients with 
rheumatoid arthritis taking hydroxychloroquine might 
also have further autoimmune conditions such as SLE 
and therefore generate the potential for confounding by 
indication. We also investigated the incidence of hyper-
lipidaemia, diabetes, venous thromboembolic disease, and 
coronary arteriosclerosis before unblinding because of the 
established evidence that hydroxychloroquine improves 
survival in patients with SLE through antilipidaemic and 
antithrombotic mechanisms of action and reduces the 
development of diabetes in patients with SLE and those 
with rheumatoid arthritis.28,37–39 We ensured that, when 
investigating covariate balance after propensity score 
stratification and matching and before unblinding study 
results, we did not see unbalanced proportions of patients 
with a diagnosis of SLE between the groups. Negative 
control outcome analyses to assess for systematic error 
also did not identify any residual unobserved con founding 
in the propensity score analysis, adjusting for thousands of 
variables within the large-scale propen sity score model. 
Although we have balanced for the coexistence of other 
conditions and medications through propensity scores, 
and we tested for residual unobserved confounding to 
ensure groups were balanced, no direct measure of severity 
of rheumatoid arthritis was drawn for patients at baseline. 
The cohort was made from patients who were new users 
of both hydroxychloroquine and sulfasalazine with a 
diagnosis of rheumatoid arthritis and without medica-
tion use in the previous 365 days, but the potential for 
differences in baseline rheumatoid arthritis severity not 
recorded in routinely collected data is also a limitation of 
the study.
Another criticism is the choice of sulfasalazine as 
an active comparator. Both hydroxychloroquine and 
sulfasalazine are second-line conventional synthetic 
disease-modifying antirheumatic drugs in the treatment 
of patients with rheumatoid arthritis, used in addition to, 
or instead of methotrexate. Although they are not fully 
equivalent to each other, and no drug can be an exact 
match, they are each the closest comparator treatment to 
the other. Appreciating they are not truly equivalent, we 
took care to ensure that propensity score stratification and 
negative control analysis for any systematic error ensured 
that the two groups were as balanced as possible to 
minimise confounding.
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Another potential limitation in this study is the potential 
for patients to be included in more than one dataset in 
the USA. Although we ran meta-analyses, which assume 
populations are independent, we highlight that we are 
likely to have underestimated variance in our meta-
analytic estimates. We also acknowledge the limitation 
that although 14 databases were used in total, mortality 
analysis was restricted to databases with good cover-
age of this outcome (ie CPRD, IMRD, IPCI, VA, and 
Clinformatics). Similarly, as we do not know the baseline 
risk of serious adverse events within this population, we 
cannot report absolute risk of these events in patients 
with rheumatoid arthritis, and this limitation must be 
acknowledged.
In this large-scale, international, real-world data network 
study, hydroxychloroquine appears to be largely safe for 
short-term use in patients with rheumatoid arthritis 
compared with sulfasalazine, but when used in com-
bination with azithromycin, this therapy carries a relative 
risk of 2·19 for cardiovascular death compared with 
hydroxychloroquine combined with amoxicillin. The 
collec tive experience of almost a million patients builds 
our confidence in the evidence around the safety profile 
of hydroxychloroquine. In line with consensus expert 
guidance, our findings suggest that a cautious assessment 
of cardiovascular risk is needed before initiating high-
dose hydroxychloroquine or hydroxychloroquine plus 
azithromycin combination therapy, and in long-term 
monitoring of patients with rheumatoid arthritis, espec-
ially those with cardiovascular risk factors.8
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